Asensus Surgical, Inc. (ASXC)
Market Cap | 189.47M |
Revenue (ttm) | 7.10M |
Net Income (ttm) | -73.55M |
Shares Out | 236.84M |
EPS (ttm) | -0.31 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,061,414 |
Open | 0.820 |
Previous Close | 0.821 |
Day's Range | 0.790 - 0.840 |
52-Week Range | 0.280 - 0.930 |
Beta | 1.38 |
Analysts | Buy |
Price Target | 2.30 (+187.5%) |
Earnings Date | Feb 27, 2023 |
About ASXC
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up ... [Read more]
Financial Performance
In 2021, ASXC's revenue was $8.23 million, an increase of 159.28% compared to the previous year's $3.18 million. Losses were -$62.46 million, 4.06% more than in 2020.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for ASXC stock is "Buy." The 12-month stock price forecast is $2.3, which is an increase of 187.50% from the latest price.
News

Asensus Surgical to Host Investor Day on February 21, 2023
RESEARCH TRIANGLE PARK, N.C., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the pati...

Asensus Surgical Receives CE Mark for Expanded Machine Vision Capabilities
Expanded Intelligent Surgical Unit™ (ISU™) capabilities include 3D measurement, digital tagging, image enhancement, and enhanced camera control, for our European customers Expanded Intelligent Surgica...

Asensus Surgical Provides Preliminary 2022 Year-End Corporate Update
RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the pati...

Asensus Surgical, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the pati...

Asensus Announces Kitakyushu General Hospital in Japan to Initiate Second Senhance System
First hospital to install a second Senhance Surgical System First hospital to install a second Senhance Surgical System

Asensus Announces Senhance Program Initiation at Kashiwa Kosei General Hospital of Japan
Continued expansion of the Senhance Program in the region Continued expansion of the Senhance Program in the region

Asensus Announces Senhance System Placement at GPR Klinikum Rüsselsheim of Germany
10th hospital in Germany to initiate a Senhance System 10th hospital in Germany to initiate a Senhance System

Asensus Announces Additional Senhance Surgical System Sale
Oncology focused hospital to initiate Senhance System program Oncology focused hospital to initiate Senhance System program

Asensus Surgical to Participate in the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) announced today that Shameze Rampertab, Executive Vice President and Chief Financial Office...

Asensus Surgical (ASXC) Reports Q3 Loss, Misses Revenue Estimates
Asensus Surgical (ASXC) delivered earnings and revenue surprises of 0% and 25.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Asensus Surgical, Inc. Reports Operating and Financial Results for the Third Quarter 2022
RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the pati...

Asensus Surgical Announces Ludwig Maximilians University in Germany to Initiate Senhance Pediatric Surgery Program
RESEARCH TRIANGLE PARK, N.C., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the pati...

Asensus Surgical, Inc. Schedules Third Quarter Financial and Operating Results Conference Call for November 10, 2022
RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient...

Asensus Surgical, Inc. To Present at The LD Micro Main Event XV
Presentation on Tuesday, October 25 at 8:30 am PTResearch Triangle Park, North Carolina--(Newsfile Corp. - October 18, 2022) - Asensus Surgical, Inc. (NYSE American: ASXC), Asensus Surgical, a medical...

Asensus Surgical Announces St. Bernhard Hospital in Germany to Initiate Senhance Surgery Program
System to be Utilized by the Oncology-Focused Clinic for General and Visceral Surgery System to be Utilized by the Oncology-Focused Clinic for General and Visceral Surgery

Asensus Surgical Announces Saiseikai Shiga Hospital in Japan to Initiate Senhance Surgery Program
RESEARCH TRIANGLE PARK, N.C., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the pat...

3 Medical Instruments Stocks to Buy Despite Industry Headwinds
The Zacks Medical - Instruments industry is growing on R&D investments. SWAV, SMLR and ASXC are set to gain the most.

Asensus Surgical to Participate in the H. C. Wainwright Global Investment Conference
RESEARCH TRIANGLE PARK, N.C., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) announced today that Anthony Fernando, President and Chief Executive Officer and Shameze Ra...

Asensus Surgical (ASXC) Reports Q2 Loss, Misses Revenue Estimates
Asensus Surgical (ASXC) delivered earnings and revenue surprises of 12.50% and 20.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Asensus Surgical Announces Sale of Senhance Robotic System
Senhance System to be placed at hospital in the Commonwealth of Independent States Senhance System to be placed at hospital in the Commonwealth of Independent States

Asensus Surgical, Inc. Schedules Second Quarter Financial and Operating Results Conference Call for August 8, 2022
RESEARCH TRIANGLE PARK, N.C., July 26, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient...

Asensus Surgical Announces Installation of Senhance Surgical System in the Department of Gynecology at University Hospital Tübingen
This becomes the 6th Senhance Hospital in Germany This becomes the 6th Senhance Hospital in Germany

Asensus Surgical to Showcase the Senhance Surgical System and Performance-Guided Surgery in Upcoming Society of Robotic and Digital Surgery Conference
RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the pati...

Asensus Surgical (ASXC) Reports Q1 Loss, Lags Revenue Estimates
Asensus Surgical (ASXC) delivered earnings and revenue surprises of 12.50% and 18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Asensus Surgical, Inc. Reports Operating and Financial Results for the First Quarter 2022
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a ...